Korean Journal of Radiology

  • 제16권4호
  • /
  • Pages.810-820
  • /
  • 2015
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

CT Perfusion Imaging Can Predict Patients' Survival and Early Response to Transarterial Chemo-Lipiodol Infusion for Liver Metastases from Colorectal Cancers

  • Lv, Wei-Fu (PET/CT Center, Qilu Hospital, First Affiliated Hospital of Shandong University) ;
  • Han, Jian-Kui (Department of Radiology, Affiliated Anhui Provincial Hospital of Anhui Medical University) ;
  • Cheng, De-Lei (Department of Radiology, Affiliated Anhui Provincial Hospital of Anhui Medical University) ;
  • Zhou, Chun-Ze (Department of Radiology, Affiliated Anhui Provincial Hospital of Anhui Medical University) ;
  • Ni, Ming (Department of Radiology, Affiliated Anhui Provincial Hospital of Anhui Medical University) ;
  • Lu, Dong (Department of Radiology, Affiliated Anhui Provincial Hospital of Anhui Medical University)
  • 투고 : 2014.10.14
  • 심사 : 2015.05.13
  • 발행 : 2015.08.01
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To prospectively evaluate the performance of computed tomography perfusion imaging (CTPI) in predicting the early response to transarterial chemo-lipiodol infusion (TACLI) and survival of patients with colorectal cancer liver metastases (CRLM). Materials and Methods: Computed tomography perfusion imaging was performed before and 1 month after TACLI in 61 consecutive patients. Therapeutic response was evaluated on CT scans 1 month and 4 months after TACLI; the patients were classified as responders and non-responders based on 4-month CT scans after TACLI. The percentage change of CTPI parameters of target lesions were compared between responders and non-responders at 1 month after TACLI. The optimal parameter and cutoff value were determined. The patients were divided into 2 subgroups according to the cutoff value. The log-rank test was used to compare the survival rates of the 2 subgroups. Results: Four-month images were obtained from 58 patients, of which 39.7% were responders and 60.3% were non-responders. The percentage change in hepatic arterial perfusion (HAP) 1 month after TACLI was the optimal predicting parameter (p = 0.003). The best cut-off value was -21.5% and patients who exhibited a ${\geq}21.5%$ decrease in HAP had a significantly higher overall survival rate than those who exhibited a < 21.5% decrease (p < 0.001). Conclusion: Computed tomography perfusion imaging can predict the early response to TACLI and survival of patients with CRLM. The percentage change in HAP after TACLI with a cutoff value of -21.5% is the optimal predictor.

키워드

참고문헌

  1. Wang DS, Louie JD, Sze DY. Intra-arterial therapies for metastatic colorectal cancer. Semin Intervent Radiol 2013;30:12-20 https://doi.org/10.1055/s-0033-1333649
  2. Gruber-Rouh T, Naguib NN, Eichler K, Ackermann H, Zangos S, Trojan J, et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer 2014;134:1225-1231 https://doi.org/10.1002/ijc.28443
  3. Leichman CG, Jacobson JR, Modiano M, Daniels JR, Zalupski MM, Doroshow JH, et al. Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: a Southwest Oncology Group pilot trial. Cancer 1999;86:775-781 https://doi.org/10.1002/(SICI)1097-0142(19990901)86:5<775::AID-CNCR12>3.0.CO;2-M
  4. Wilcox RA, Djulbegovic B, Moffitt HL, Guyatt GH, Montori VM. Randomized trials in oncology stopped early for benefit. J Clin Oncol 2008;26:18-19 https://doi.org/10.1200/JCO.2007.13.6259
  5. Konopke R, Roth J, Volk A, Pistorius S, Folprecht G, Zophel K, et al. Colorectal liver metastases: an update on palliative treatment options. J Gastrointestin Liver Dis 2012;21:83-91
  6. Whisenant J, Venook A. Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer. Oncology (Williston Park) 2004;18:762-768; discussion 769-773
  7. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J 2010;16:163-175 https://doi.org/10.1097/PPO.0b013e3181d7e8cf
  8. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009;250:466-473 https://doi.org/10.1148/radiol.2502072222
  9. Li Z, Bonekamp S, Halappa VG, Corona-Villalobos CP, Pawlik T, Bhagat N, et al. Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization. Radiology 2012;264:97-109 https://doi.org/10.1148/radiol.12112161
  10. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115:616-623 https://doi.org/10.1002/cncr.24050
  11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390 https://doi.org/10.1056/NEJMoa0708857
  12. Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, Li Z, Reyes D, Cosgrove D, et al. Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology 2013;266:502-513 https://doi.org/10.1148/radiol.12120495
  13. Anzidei M, Napoli A, Zaccagna F, Cartocci G, Saba L, Menichini G, et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. J Comput Assist Tomogr 2011;35:690-696 https://doi.org/10.1097/RCT.0b013e318230d905
  14. Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012;47:11-17 https://doi.org/10.1097/RLI.0b013e3182199bb5
  15. Yang L, Zhang XM, Zhou XP, Tang W, Guan YS, Zhai ZH, et al. Correlation between tumor perfusion and lipiodol deposition in hepatocellular carcinoma after transarterial chemoembolization. J Vasc Interv Radiol 2010;21:1841-1846 https://doi.org/10.1016/j.jvir.2010.08.015
  16. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009;250:281-289 https://doi.org/10.1148/radiol.2501080295
  17. Wang X, Xue HD, Jin ZY, Su BY, Li Z, Sun H, et al. Quantitative hepatic CT perfusion measurement: comparison of Couinaud's hepatic segments with dual-source 128-slice CT. Eur J Radiol 2013;82:220-226 https://doi.org/10.1016/j.ejrad.2012.09.015
  18. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010;116:1305-1314 https://doi.org/10.1002/cncr.24884
  19. Islam R, Chyou PH, Burmester JK. Modeling efficacy of bevacizumab treatment for metastatic colon cancer. J Cancer 2013;4:330-335 https://doi.org/10.7150/jca.6083
  20. Morsbach F, Sah BR, Spring L, Puippe G, Gordic S, Seifert B, et al. Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques. Eur Radiol 2014;24:1455-1465 https://doi.org/10.1007/s00330-014-3180-3
  21. Reiner CS, Morsbach F, Sah BR, Puippe G, Schaefer N, Pfammatter T, et al. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion. J Vasc Interv Radiol 2014;25:747-759 https://doi.org/10.1016/j.jvir.2014.01.025
  22. Morsbach F, Pfammatter T, Reiner CS, Fischer MA, Sah BR, Winklhofer S, et al. Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases. Invest Radiol 2013;48:787-794 https://doi.org/10.1097/RLI.0b013e31829810f7
  23. Singh J, Sharma S, Aggarwal N, Sood RG, Sood S, Sidhu R. Role of perfusion CT differentiating hemangiomas from malignant hepatic lesions. J Clin Imaging Sci 2014;4:10 https://doi.org/10.4103/2156-7514.127959
  24. Kruskal JB, Kane RA. Pathophysiology of hepatic perfusion changes in livers containing small or occult metastases. Radiology 1998;209:291-292
  25. Miles KA, Leggett DA, Kelley BB, Hayball MP, Sinnatamby R, Bunce I. In vivo assessment of neovascularization of liver metastases using perfusion CT. Br J Radiol 1998;71:276-281 https://doi.org/10.1259/bjr.71.843.9616236
  26. Choi SH, Chung JW, Kim HC, Baek JH, Park CM, Jun S, et al. The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. Invest Radiol 2010;45:427-436
  27. Ng CS, Chandler AG, Wei W, Herron DH, Anderson EF, Kurzrock R, et al. Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology 2011;260:762-770 https://doi.org/10.1148/radiol.11110331
  28. Ippolito D, Sironi S, Pozzi M, Antolini L, Invernizzi F, Ratti L, et al. Perfusion CT in cirrhotic patients with early stage hepatocellular carcinoma: assessment of tumor-related vascularization. Eur J Radiol 2010;73:148-152 https://doi.org/10.1016/j.ejrad.2008.10.014
  29. Ghanaati H, Mohammadzadeh V, Mohammadzadeh A, Firouznia K, Mohammadzadeh M, Motevali M, et al. Efficacy of transarterial chemoembolization on lesion reduction in colorectal liver metastases. Acta Med Iran 2012;50:535-540
  30. Thng CH, Koh TS, Collins DJ, Koh DM. Perfusion magnetic resonance imaging of the liver. World J Gastroenterol 2010;16:1598-1609 https://doi.org/10.3748/wjg.v16.i13.1598
  31. Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology 2007;243:736-743 https://doi.org/10.1148/radiol.2433052020
  32. Jiang ZX, Peng WJ, Li WT, Tang F, Liu SY, Qu XD, et al. Effect of b value on monitoring therapeutic response by diffusion-weighted imaging. World J Gastroenterol 2008;14:5893-5899 https://doi.org/10.3748/wjg.14.5893
  33. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011;55:1309-1316 https://doi.org/10.1016/j.jhep.2011.03.007
  34. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012;262:708-718 https://doi.org/10.1148/radiol.11110282
  35. Yeo DM, Choi JI, Lee YJ, Park MY, Chun HJ, Lee HG. Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads. J Comput Assist Tomogr 2014;38:391-397 https://doi.org/10.1097/RCT.0000000000000070

피인용 문헌

  1. Value or waste: Perfusion imaging following radiofrequency ablation - early experience vol.61, pp.2, 2015, https://doi.org/10.3233/ch-152000
  2. Early Response of Hepatocellular Carcinoma to Chemoembolization: Volume Computed Tomography Liver Perfusion Imaging as a Short-Term Response Predictor vol.41, pp.2, 2017, https://doi.org/10.1097/rct.0000000000000511
  3. Evaluation of Multislice Spiral Computed Tomography Perfusion Imaging for the Efficacy of Preoperative Concurrent Chemoradiotherapy in Middle-Aged and Elderly Patients with Locally Advanced Gastric Ca vol.24, pp.None, 2015, https://doi.org/10.12659/msm.905143
  4. Perfusion Computer Tomography Assessment of the Effect of Angiotensin II On Blood Flow Distribution in Rabbits with Intrarenal VX2 Tumors vol.47, pp.1, 2015, https://doi.org/10.1159/000489752
  5. Investigation of the values of CT perfusion imaging and ultrasound elastography in the diagnosis of liver fibrosis vol.16, pp.2, 2015, https://doi.org/10.3892/etm.2018.6269
  6. Prediction of Treatment Outcome of Chemotherapy Using Perfusion Computed Tomography in Patients with Unresectable Advanced Gastric Cancer vol.20, pp.4, 2015, https://doi.org/10.3348/kjr.2018.0306
  7. Dynamic Contrast-Enhanced Ultrasound of Gastric Cancer: Correlation with Perfusion CT and Histopathology vol.20, pp.5, 2019, https://doi.org/10.3348/kjr.2018.0273
  8. A Systematic Review on the Role of the Perfusion Computed Tomography in Abdominal Cancer vol.19, pp.4, 2021, https://doi.org/10.1177/15593258211056199